An Intensive QT/QTc Study to Investigate the Effects of Rovalpituzumab Tesirine on Cardiac Ventricular Repolarization in Subjects With Small Cell Lung Cancer
Phase of Trial: Phase I
Latest Information Update: 14 Jul 2017
At a glance
- Drugs Rovalpituzumab tesirine (Primary)
- Indications Small cell lung cancer
- Focus Adverse reactions
- Sponsors Stemcentrx
- 07 Jul 2017 Planned primary completion date changed from 1 Jun 2017 to 1 Jan 2018.
- 21 Sep 2016 Status changed from not yet recruiting to recruiting.
- 25 Aug 2016 New trial record